Unlock the therapeutic potential of targeted protein degradation with deep proteomic screening
Targeted protein degradation (TPD) is a powerful therapeutic modality to eliminate disease-causing proteins that are resistant to conventional drugs. In this webinar, we present a high-throughput scalable proteomics approach that utilizes label-free, single-shot dia-PASEF® mass spectrometry to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed. A combination of DIA-NN software and advanced statistical tools guarantees rapid, automated analysis of large proteomics datasets with highest precision of quantification, data completeness and sensitivity. A slice-PASEF-based global ubiquitinomics approach will be presented that verifies degrader-induced modifications with an unprecedented depth of 50,000 ubiquitination sites. In addition, a data analysis suite designed for user-friendly evaluation and in-depth meta-analysis will be shown, making proteomics data easily accessible for target identification, SAR optimization, library expansion and strategic drug discovery decisions.
About NEOsphere Biotechnologies:
NEOsphere Biotechnologies is a leading partner in TPD (Targeted Protein Degradation) proteomics, collaborating with pharmaceutical and biotechnology companies to advance drug discovery and develop innovative degrader pipelines. The platform combines cutting-edge mass spectrometry technologies with advanced biostatistical data analysis, enabling high-throughput proteomic screening of entire degrader libraries and mechanistic target validation, including global ubiquitinomics. NEOsphere Biotechnologies offers unmatched sensitivity, precision, and turnaround times, facilitating the large-scale identification of novel degrader targets and the systematic exploration of previously undruggable therapeutic targets.
You will learn about:
- A high-throughput proteomics approach that utilizes label-free, single-shot dia-PASEF to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed
- The verification of degrader-induced modifications using an optimized acquisition strategy based on slice-PASEF-based global ubiquitinomics
- The benefit of combining the capabilities of a timsTOF HT and a timsTOF Ultra 2
Presenter: Uli Ohmayer, Ph.D. (Head of Mass Spectrometry and Founder, NEOsphere Biotechnologies GmbH, Munich, Germany)
